Half-year report · Q2

Period2024-12-01 → 2025-05-31
Filed2025-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥4.3bn2024-12-01 → 2025-05-31Cons.Net sales
Revenue¥8.9bn2023-12-01 → 2024-11-30Cons.Net sales (5-year summary)
Revenue¥4.2bn2023-12-01 → 2024-05-31Cons.Net sales
Operating income¥199m2024-12-01 → 2025-05-31Cons.Operating income
Operating income¥202m2023-12-01 → 2024-05-31Cons.Operating income
Ordinary income¥183m2024-12-01 → 2025-05-31Cons.Ordinary income
Ordinary income¥390m2023-12-01 → 2024-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥212m2023-12-01 → 2024-05-31Cons.Ordinary income
Profit before tax¥183m2024-12-01 → 2025-05-31Cons.Income before income taxes
Profit before tax¥252m2023-12-01 → 2024-05-31Cons.Income before income taxes
Net income (owners)¥135m2024-12-01 → 2025-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥336m2023-12-01 → 2024-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥193m2023-12-01 → 2024-05-31Cons.Profit loss attributable to owners of parent
Net income¥135m2024-12-01 → 2025-05-31Cons.Profit loss
Net income¥193m2023-12-01 → 2024-05-31Cons.Profit loss
Total assets¥8.8bnat 2025-05-31Cons.Assets
Total assets¥8.5bnat 2024-11-30Cons.Assets
Total assets¥8.0bnat 2024-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.8bnat 2025-05-31Cons.Liabilities
Total liabilities¥5.6bnat 2024-11-30Cons.Liabilities
Net assets / equity¥2.9bnat 2025-05-31Cons.Net assets
Net assets / equity¥2.9bnat 2024-11-30Cons.Net assets
Net assets / equity¥2.7bnat 2024-05-31Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2025-05-31Cons.Cash and deposits
Cash and deposits¥745mat 2024-11-30Cons.Cash and deposits
Cash & equivalents¥1.3bnat 2025-05-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-11-30Cons.Cash and cash equivalents
Cash & equivalents¥947mat 2024-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.0bnat 2023-11-30vCons.Cash and cash equivalents
Operating cash flow¥566m2024-12-01 → 2025-05-31Cons.Net cash provided by used in operating activities
Operating cash flow¥143m2023-12-01 → 2024-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥90m2023-12-01 → 2024-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥216m2024-12-01 → 2025-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥305m2023-12-01 → 2024-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2023-12-01 → 2024-05-31Cons.Net cash provided by used in investment activities
Financing cash flow¥187m2024-12-01 → 2025-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥139m2023-12-01 → 2024-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥101m2023-12-01 → 2024-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥110.522024-12-01 → 2025-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥276.222023-12-01 → 2024-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥158.382023-12-01 → 2024-05-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio33.5%at 2025-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio33.8%at 2024-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.2%at 2024-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2024-12-01 → 2025-05-31¥4.3bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2024-12-01 → 2025-05-31¥4.3bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2024-12-01 → 2025-05-31¥184m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2024-12-01 → 2025-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2024-12-01 → 2025-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2024-12-01 → 2025-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2024-12-01 → 2025-05-31¥4.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-12-01 → 2025-05-31¥4.3bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-12-01 → 2025-05-31¥199m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2023-12-01 → 2024-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2023-12-01 → 2024-05-31¥187m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2023-12-01 → 2024-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2023-12-01 → 2024-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-12-01 → 2024-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-12-01 → 2024-05-31¥202m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 484
ItemContextValueUnit
Depreciation and amortization ope cfPrior1YTDDuration200147000JPY
Depreciation and amortization ope cfCurrentYTDDuration197749000JPY
Increase decrease in allowance for doubtful accounts ope cfPrior1YTDDuration-637000JPY
Increase decrease in allowance for doubtful accounts ope cfCurrentYTDDuration-631000JPY
Increase decrease in net defined benefit liability ope cfPrior1YTDDuration-68600000JPY
Increase decrease in net defined benefit liability ope cfCurrentYTDDuration-24384000JPY
Increase decrease in provision for directors bonuses ope cfPrior1YTDDuration-10500000JPY
Increase decrease in provision for directors bonuses ope cfCurrentYTDDuration-12450000JPY
Increase decrease in provision for directors retirement benefits ope cfPrior1YTDDuration2718000JPY
Increase decrease in provision for directors retirement benefits ope cfCurrentYTDDuration10953000JPY
Interest and dividends income ope cfPrior1YTDDuration-2617000JPY
Interest and dividends income ope cfCurrentYTDDuration-2957000JPY
Foreign exchange losses gains ope cfPrior1YTDDuration-588000JPY
Foreign exchange losses gains ope cfCurrentYTDDuration558000JPY
Interest expenses paid on loans and bonds ope cfPrior1YTDDuration9474000JPY
Interest expenses paid on loans and bonds ope cfCurrentYTDDuration17025000JPY
Loss on retirement of noncurrent assets ope cfPrior1YTDDuration2146000JPY
Loss on retirement of noncurrent assets ope cfCurrentYTDDuration233000JPY
Loss gain on sales of investment securities ope cfPrior1YTDDuration-42660000JPY
Loss gain on sales of investment securities ope cfCurrentYTDDuration-JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1YTDDuration375010000JPY
Decrease increase in notes and accounts receivable trade ope cfCurrentYTDDuration370981000JPY
Decrease increase in inventories ope cfPrior1YTDDuration-250730000JPY
Decrease increase in inventories ope cfCurrentYTDDuration242818000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1YTDDuration-121917000JPY
Increase decrease in notes and accounts payable trade ope cfCurrentYTDDuration-263785000JPY
Increase decrease in accrued consumption taxes ope cfPrior1YTDDuration-103676000JPY
Increase decrease in accrued consumption taxes ope cfCurrentYTDDuration24285000JPY
Other net ope cfPrior1YTDDuration-116207000JPY
Other net ope cfCurrentYTDDuration-120469000JPY
Subtotal ope cfPrior1YTDDuration123761000JPY
Subtotal ope cfCurrentYTDDuration623029000JPY
Interest and dividends income received ope cf inv cfPrior1YTDDuration2617000JPY
Interest and dividends income received ope cf inv cfCurrentYTDDuration2957000JPY
Interest expenses paid ope cf fin cfPrior1YTDDuration-9498000JPY
Interest expenses paid ope cf fin cfCurrentYTDDuration-17061000JPY
Income taxes paid ope cfPrior1YTDDuration-27294000JPY
Income taxes paid ope cfCurrentYTDDuration-42433000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration89585000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration566492000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-143412000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-215670000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-428000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-688000JPY
Proceeds from sales of investment securities inv cfPrior1YTDDuration44609000JPY
Proceeds from sales of investment securities inv cfCurrentYTDDuration-JPY
Other net inv cfPrior1YTDDuration3021000JPY
Other net inv cfCurrentYTDDuration101000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-96210000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-216257000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-11-30pass rounding
balance sheet identityconsolidated 2025-05-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-11-30pass
statement vs summary · net assetsconsolidated 2025-05-31pass
statement vs summary · net income attributable to parentconsolidated 2023-12-01/2024-05-31pass
statement vs summary · net income attributable to parentconsolidated 2024-12-01/2025-05-31pass
statement vs summary · operating cash flowconsolidated 2023-12-01/2024-05-31pass
statement vs summary · operating cash flowconsolidated 2024-12-01/2025-05-31pass
statement vs summary · revenueconsolidated 2023-12-01/2024-05-31pass
statement vs summary · revenueconsolidated 2024-12-01/2025-05-31pass
statement vs summary · total assetsconsolidated 2024-11-30pass
statement vs summary · total assetsconsolidated 2025-05-31pass